S
STAT-Dx
Develops near-patient testing products for healthcare professionals
About STAT-Dx
Stat-Dx, a subsidiary of QIAGEN, specializes in multiplex syndromic testing solutions that enable rapid and accurate diagnosis of respiratory and gastrointestinal infections. The company serves healthcare providers, clinical laboratories, and research institutions, operating primarily in the medical diagnostics market. Stat-Dx's flagship product, the QIAstat Dx Analyzer, uses advanced technology to simultaneously detect and differentiate multiple pathogens from a single sample, significantly reducing the time and labor involved in traditional diagnostic methods. The business model revolves around the sale of diagnostic panels and cartridges, which are used with the QIAstat Dx Analyzer. Revenue is generated through the sale of these consumables and the analyzer itself. Stat-Dx's innovative approach addresses the critical need for timely and precise diagnostic information, particularly in the context of infectious diseases like COVID-19. The company’s products are designed to meet the demands of both routine clinical diagnostics and urgent public health challenges, offering a valuable tool for clinicians and researchers alike.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2010
- Headquarters
- Barcelona, Spain
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 63.9/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Hard Tech, medical testing, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Feb 2018 | $191M | $191M | Qiagen | — |
| EARLY VC✓Equity / VC | Oct 2016 | — | — | N47 | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for STAT-Dx is 640 monthly website visits, up 276.5% over the last three months. STAT-Dx's team declined 70.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Ysios Capital
Kurma Partners
Criteria Venture Tech
Boehringer Ingelheim Venture Fund
Eurazeo
ADIN
Series B and later3 investors entered at this stage
PT AXIS Telekom Indonesia
Gilde Healthcare
N47
Other known investors1 additional known investor
Qiagen
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about STAT-Dx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See STAT-Dx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.